Prostate Cancer Radiotherapy Study Findings Released
Researchers analyzed outcomes for men treated with radiation for prostate cancer with positive pelvic lymph nodes.
Updated on Oct. 12, 2026 in Cancer
Live Poll
Do you trust that new multi-modal therapies significantly improve long-term cancer outcomes?
A retrospective study presented at the 2026 ASTRO annual meeting evaluated the efficacy of elective pelvic nodal radiotherapy in 1,166 men. The research focused on patients treated between 2014 and 2024 to address limited data regarding oligometastatic spread.
Why it matters
Understanding outcomes for men with mesorectal, peri-aortic, or oligometastatic bony disease is critical, as existing clinical data for these specific presentations remains limited. This analysis helps clarify how treatment regimens impact long-term survival and progression for complex cases.
The study utilized a cohort of 1,166 men, with 94% receiving androgen deprivation therapy and 79% undergoing treatment with androgen receptor pathway inhibitors. Patients were administered elective pelvic lymph node radiotherapy at doses ranging from 45 to 46.8 Gy.
The players
Jade Dodge
Jade Dodge is the researcher who presented the retrospective study results at the 2026 ASTRO annual meeting.
ASTRO
ASTRO is the American Society for Radiation Oncology, a professional organization dedicated to improving patient care in radiation oncology.
The details
Researchers employed Kaplan-Meier analysis to evaluate survival outcomes and used multivariable Cox-proportional hazard models to assess clinicodemographic variables. The study found that M1b disease correlated with worse biochemical and distant metastasis-free survival compared to M1a disease, though overall survival rates did not differ significantly.
Timeline
The treatment period for patients in the study occurred between 2014 and 2024.
The 68th Annual ASTRO Meeting took place in Boston from September 26-30, 2026.
The Big Picture
This study follows the established pattern of using the ASTRO annual meeting to present findings from large-scale retrospective clinical reviews.
These findings help oncologists refine radiation protocols for patients presenting with positive pelvic lymph nodes or metastatic disease. The study highlights significant differences in disease progression between M1a and M1b classifications, which may influence personalized treatment plans.
The takeaway
This research emphasizes the importance of classifying metastatic spread, as M1b cases showed a distinct risk profile compared to M1a cases. Patients with similar diagnoses should discuss these specific progression risks with their clinical teams to better understand their prognosis.
Further reading
For more information on current treatment trends, visit the Cancer section.
Source note: This article includes information reported by Urotoday.
Live Poll
Do you trust that new multi-modal therapies significantly improve long-term cancer outcomes?
